The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

UK pharma major AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

British drugmaker AstraZeneca (LSE: AZN) has gained European approval for Imfinzi (durvalumab) in combination with ...

London has struggled for several years to attract big-name IPOs amid a dearth of liquidity and a less favourable regulatory climate, with reforms last year so far failing to arrest the decline.

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Shares in TripAdvisor (TRIP) were in the red in after hours trading after surging by 16% in Thursday's session as it was ...

The FTSE 100 and European stocks were jittery on Friday, moving lower while US markets were closed for 4 July, as investors ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

Shaw's remarks come after Siddaramaiah defended his decision to order an inquiry into recent heart-related deaths in Hassan.